CN103432173B - Fermented fermentative cordycep fungal powder compound preparation - Google Patents
Fermented fermentative cordycep fungal powder compound preparation Download PDFInfo
- Publication number
- CN103432173B CN103432173B CN201310392296.1A CN201310392296A CN103432173B CN 103432173 B CN103432173 B CN 103432173B CN 201310392296 A CN201310392296 A CN 201310392296A CN 103432173 B CN103432173 B CN 103432173B
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound preparation
- cordyceps fungus
- crude drug
- fungus powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 241000190633 Cordyceps Species 0.000 title claims abstract description 34
- 239000000843 powder Substances 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 230000002538 fungal effect Effects 0.000 title abstract 3
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- 230000004151 fermentation Effects 0.000 claims description 25
- 238000000855 fermentation Methods 0.000 claims description 25
- 239000009636 Huang Qi Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 9
- 239000011812 mixed powder Substances 0.000 claims description 8
- 239000012567 medical material Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract description 8
- 206010006451 bronchitis Diseases 0.000 abstract description 8
- 208000007451 chronic bronchitis Diseases 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 208000006673 asthma Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 210000004072 lung Anatomy 0.000 abstract description 5
- 238000005728 strengthening Methods 0.000 abstract description 4
- 206010021143 Hypoxia Diseases 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 201000006306 Cor pulmonale Diseases 0.000 abstract description 2
- 206010014561 Emphysema Diseases 0.000 abstract description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 abstract description 2
- 201000000258 compensatory emphysema Diseases 0.000 abstract description 2
- 210000002216 heart Anatomy 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 230000002612 cardiopulmonary effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- -1 hydroxypropyl Chemical group 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a fermented fermentative cordycep fungal powder compound preparation for improving sub-health status and common respiratory system diseases. The technical scheme is as follows: the compound preparation is prepared from the following raw materials by weight: 0.1-0.4g of fermented fermentative cordycep fungal powder, 0.05-0.3g of astragalus membranaceus and 0.01-0.2g of rhodiola rosea. The compound preparation has the effects of invigorating lung and kidney, benefiting vital energy for activating blood, tonifying vital energy for strengthening foundation, dredging veins for relieving asthma, regulating vital energy and blood, supplementing yin and yang, improving heart, lung, kidney and spleen functions, regulating yin and yang balance of a human body, keeping fitness, improving immunity and resisting fatigue and hypoxia, and is used for auxiliary treatment of diseases such as plateau compensatory emphysema, pulmonary heart disease and chronic bronchitis.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation that improves sub-health state, improves respiratory system commonly encountered diseases, be specifically related to a kind of fermentation Cordyceps fungus powder compound preparation.
Background technology
Quickening along with people's life, work rhythm, operating pressure increases, the pollutions such as while waste gas, rubbish, industry, noise and ray, grievous injury people's living environment, cause the crowd of health in subhealth state to roll up, the crowd who especially suffers from respiratory system disease significantly increases.Chronic pharyngolaryngitis and chronic bronchitis, cough is a kind of common respiratory disorder, and main manifestations bottleneck throat is uncomfortable, and sound is bad-looking, even hoarseness, cough, asthma, uncomfortable in chest, hypopnea etc.These diseases usually affect people's life with healthy.Therefore improve sub-health state, improve respiratory system commonly encountered diseases and just seem significant.
The present invention is not by supporting conditioning to the body fluid of human body, QI and blood, with science production technology, provides a kind of and can effectively improve sub-health state, treats the fermentation Cordyceps compound preparation of above-mentioned disease.The Radix Astragali is warm in nature, Cordyceps property is flat, Radix Rhodiolae is flat, and the Cordyceps powder that the master of take in prescription enters lung kidney YIN nourishing is as main, and the Radix Rhodiolae that master enters cardiopulmonary strengthening QI and blood is auxiliary, the effectiveness of strengthening to cardio-pulmonary function, the Radix Astragali is assisted a ruler in governing a country to regulate the flow of vital energy and is consolidated, and is better than QI invigorating, helps fate row, the flat tepor of globality, is suitable for crowd's use that various body deficiency syndrome are waited.
This prescription nature and flavor are gentleer, major function is flat nourishing YIN sun, take into account the five internal organs, the outstanding adjusting of the function to respiratory system and cardiovascular system, be applicable to multiple sub-health population and have a delicate constitution, crowd lower for the resistance, the use of strengthening to the crowd such as high originality respiratory system disease, compensatory high altitude anoxia and fatigue recovery, senile respiratory circulatory system diseases, hypofunction be weak, contribute to the recovery of the operation of body qi-blood-body fluid and equilibrium between yin and yang, also comprised many other comprehensive effects simultaneously.
Summary of the invention
Inventor is through preliminary screening and comparison, selecting Radix Rhodiolae and the Radix Astragali is prescription raw material, related request according to national drug management carries out the research of system complete, developed the medicine with obvious therapeutic effect, can invigorating the lung and the kidney, benefiting QI for activating blood circulation, QI invigorating consolidates, promote blood circulation and relieving asthma, QI and blood regulating, flat nourishing YIN sun.Improve cardiopulmonary kidney splenic function, regulate body equilibrium between yin and yang, building body.There is the function that improves immunity, resisting fatigue anti-hypoxia, for the auxiliary treatment of the diseases such as plateau compensatory emphysema, pulmonary heart disease, chronic bronchitis.
Formula of the present invention forms: a kind of fermentation Cordyceps fungus powder Chinese medicine preparation, by weight, by following crude drug, made: fermentation Cordyceps fungus powder 0.1-0.4g, Radix Astragali 0.05-0.3g, Radix Rhodiolae 0.01-0.2g.
Preferred: fermentation Cordyceps fungus powder 0.2-0.4g, the Radix Astragali 0.1-0.3g, Radix Rhodiolae 0.02-0.2g.
Further preferably: fermentation Cordyceps fungus powder 0.2-0.3g, the Radix Astragali 0.1-0.2g, Radix Rhodiolae 0.03-0.1g.
Most preferably: fermentation Cordyceps fungus powder 0.25g, Radix Astragali 0.15g, Radix Rhodiolae 0.05g.
The preparation method of preparation of the present invention comprises the following steps:
(1) according to crude drug part by weight, take Chinese crude drug, clean;
(2) by above-mentioned, clean rear medical material co-grinding powdered, cross 40 mesh sieves, obtain mixed-powder;
(3) mixed-powder of step (2) gained is become to pharmaceutically acceptable preparation as active fraction preparation.
Or:
(1) according to crude drug part by weight, take Chinese crude drug, clean;
(2) by above-mentioned, clean rear medical material and mix, be ground into coarse powder, add 6-1.0 times of water gaging, soak 11-5 hour, decoct 1-3 time, each 1-3 hour, filters merging filtrate, the clear paste that while being evaporated to 60 ℃ of heat surveys, relative density is 1.20-11.25, add that ethanol is standing, precipitate with ethanol, filtration, decompression filtrate recycling ethanol is to without alcohol taste, the fluid extract of relative density 1.00-1.10 when being evaporated to 60 ℃ of heat and surveying;
(3) fluid extract of step (2) gained is prepared into pharmaceutically acceptable preparation.
In preparation of the present invention, described Traditional Chinese medicine health-preserving preparation formulation is capsule, tablet, granule, powder or oral liquid for above-mentioned dosage form can be realized, can add the acceptable adjuvant of pharmacy, for example: filler when these dosage forms of preparation, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene is fixed, Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
The specific embodiment
Following examples crude drug Jun Gou BAIYAO city process are identified.
The preparation of embodiment 1 fermentation Cordyceps compound capsule:
Get crude drug: fermentation Cordyceps fungus powder 0.25g, Radix Astragali 0.15g, Radix Rhodiolae 0.05g.
(1) according to crude drug part by weight, take Chinese crude drug, clean;
(2) by above-mentioned, clean rear medical material co-grinding powdered, cross 40 mesh sieves, obtain mixed-powder;
(3) using the mixed-powder of step (2) gained as active component, mix with appropriate amount of starch, after sieving, fully mix, be distributed in capsule and get final product, every 0.2g or every 0.4g.
The preparation of embodiment 2 fermentation Cordyceps compound oral liquids:
Get crude drug: fermentation Cordyceps fungus powder 0.4g, Radix Astragali 0.3g, Radix Rhodiolae 0.2g.
(1) according to crude drug part by weight, take Chinese crude drug, clean;
(2) by above-mentioned, clean rear medical material and mix, be ground into coarse powder, add 9 times of water gagings, soak 2 hours, decoct 2 times, each 2 hours, filter merging filtrate, the clear paste that while being evaporated to 60 ℃ of heat surveys, relative density is 1.20-1.25, add that ethanol is standing, precipitate with ethanol, filtration, decompression filtrate recycling ethanol is to without alcohol taste, the fluid extract of relative density 1.00-1.10 when being evaporated to 60 ℃ of heat and surveying;
(3) by the appropriate distilled water diluting of fluid extract of step (2) gained, filter, diluent is 20% containing crude drug amount, adds simple syrup, potassium sorbate, makes.
The preparation of embodiment 3 fermentation Cordyceps compound tablet:
Get crude drug: fermentation Cordyceps fungus powder 10g, Radix Astragali 5g, Radix Rhodiolae 1g.
(, 1) and according to crude drug part by weight, take Chinese crude drug, clean;
(2) by above-mentioned, clean rear medical material co-grinding powdered, cross 40 mesh sieves, obtain mixed-powder;
(3) using the mixed-powder of step (2) gained as active component, with appropriate amount of starch, Pulvis Talci and magnesium stearate, mix direct compression and get final product after sieving.Every 0.4g.
Embodiment 4 model cases:
1, open in the 120 routine volunteers (55-65 years old ages) such as XX, be divided at random 3 groups, A group 40 examples are healthy person; B organizes 40 routine physical weakness, hypoimmunity, and often flu, on average all catches a cold once every half a year; C organizes 40 examples and has a delicate constitution equally, hypoimmunity, and often flu, on average all catches a cold once every half a year.A group and B organize each 4 of the capsules of equal every day of embodiment 1 preparation sooner or later bfore meals, and C group every day is non-activity composition bfore meals sooner or later, respectively 4 of the capsules only packing into starch.Take continuously 1 year, other living habit is with identical at ordinary times.Through follow-up investigation, result: in A group, 38 people are energetic, 2 people's flu are once; In B group, 34 people do not catch a cold, and once, 3 people catch a cold twice to 3 people's flu, and all energy is day by day abundant; C group has no the improvement of health status, and only 10 people do not catch a cold, 8 people's flu once, 15 people catch a cold that twice, 7 people catches a cold 3 times or more than.
Clinical research shows, the preparation tool of the present invention sub-health status that improves significantly improves the effect of body immunity.
2, select chronic bronchitis patient 240 examples receive treatment voluntarily, male 120 examples, female's 120 examples, age 38-56 year, average 45 years old.Patient is prolonged and repeated cough, expectoration, asthma, infection all, show effect every year at least March, and continue more than 2 years, and eliminating heart and lung diseases, be that its clinical symptoms, sign inspection all meet chronic bronchitis diagnostic criteria, be not in the mood for, the complication such as liver, kidney, hemopoietic system, can be diagnosed as chronic bronchitis.Be divided at random A group, B group, C group, D group, E group, every group of 40 examples; Each organizes patient age symptom formation without significant difference, has comparability (P>0.05).
A, B, C, D, E are treatment group, and Primary Care is consistent, and C group, for matched group, is not taken medicine.The embodiment of the present invention 3 for A group, every day three times, one time 1.B group cefalexin, each 0.25g, every day 4 times.C group adopts prepared by method similarly to Example 3 only take the tablet that fermentation Cordyceps fungus powder prepared as crude drug, every day three times, one time 1.D group adopts prepared by method similarly to Example 3 only take the tablet that the Radix Astragali prepared as crude drug, every day three times, one time 1.E group adopts prepared by method similarly to Example 3 only take the tablet that Radix Rhodiolae prepared as crude drug, every day three times, one time 1.It within 30th, is a course for the treatment of.
Disease Diagnosis Standard: recovery from illness: all oneself recovers normal for symptom, sign inspection and x-ray rabat, and expectorant bacterium is cultivated negative; Effective: symptom, sign inspection recover normal, and expectorant bacterium is cultivated and turns out cloudy, x-ray rabat inflammatory lesion basic absorption; Progressive: sings and symptoms alleviates to some extent, and x-ray rabat inflammatory lesion partially absorbs; Invalid: the state of an illness is not improved or increases the weight of to some extent.
Result is as follows:
| ? | Cure | Effective | Progressive | Invalid | Effective percentage |
| A group | 16 | 14 | 7 | 3 | 92.5％ |
| B group | 14 | 14 | 8 | 4 | 90％ |
| C group | 7 | 7 | 11 | 15 | 62.5％ |
| D group | 0 | 2 | 4 | 34 | 15％ |
| E group | 3 | 5 | 6 | 26 | 35％ |
| Matched group | 0 | 0 | 0 | 40 | 0％ |
Aged debility is normally hindered accumulation and is caused due to deficiency of YIN yang deficiency or deficiency of both YIN and YANG because multiple strain is empty, and the normally basic inducement of deficiency of vital energy damage of essence, and cordyceps sinensis lung-reinforcing nourishing kidney in this prescription, the antitussive of relievining asthma, conditioning lung and kidney function; Radix Astragali QI invigorating consolidates, and promotes vigour, improves deficiency of vital energy syndrome; Radix Rhodiolae benefiting QI for activating blood circulation, promotes blood circulation and relievings asthma, and improves cardio-pulmonary function.
And as can be seen from the above results, although Cordyceps, the Radix Astragali and Radix Rhodiolae all can play respectively the effect of certain treatment chronic bronchitis, but its compositions has produced obvious synergistic function, fermentation Cordyceps compound preparation provided by the invention can effectively be treated chronic bronchitis.
Claims (8)
1. a fermentation Cordyceps fungus powder compound preparation, is characterized in that: by weight, by following crude drug, made: fermentation Cordyceps fungus powder 0.1-0.4g, Radix Astragali 0.05-0.3g, Radix Rhodiolae 0.01-0.2g.
2. a kind of fermentation Cordyceps fungus powder compound preparation according to claim 1, is characterized in that: by weight, by following crude drug, made: fermentation Cordyceps fungus powder 0.2-0.4g, Radix Astragali 0.1-0.3g, Radix Rhodiolae 0.02-0.2g.
3. a kind of fermentation Cordyceps fungus powder compound preparation according to claim 1, is characterized in that: by weight, by following crude drug, made: fermentation Cordyceps fungus powder 0.2-0.3g, Radix Astragali 0.1-0.2g, Radix Rhodiolae 0.03-0.1g.
4. a kind of fermentation Cordyceps fungus powder compound preparation according to claim 1, is characterized in that: by weight, by following crude drug, made: fermentation Cordyceps fungus powder 0.25g, Radix Astragali 0.15g, Radix Rhodiolae 0.05g.
5. according to a kind of fermentation Cordyceps fungus powder compound preparation described in claim 1-4 any one, it is characterized in that: described Chinese medicine preparation dosage form is capsule, tablet, granule, powder or oral liquid.
6. according to the preparation method of a kind of Cordyceps fungus powder compound preparation that ferments described in claim 1-5 any one, it is characterized in that: comprise the following steps:
(1) according to crude drug part by weight, take Chinese crude drug, clean;
(2) by above-mentioned, clean rear medical material co-grinding powdered, cross 40 mesh sieves, obtain mixed-powder;
(3) mixed-powder of step (2) gained is become to pharmaceutically acceptable preparation as active fraction preparation.
7. according to the preparation method of a kind of Cordyceps fungus powder compound preparation that ferments described in claim 1-5 any one, it is characterized in that: comprise the following steps:
(1) according to crude drug part by weight, take Chinese crude drug, clean;
(2) by above-mentioned, clean rear medical material and mix, be ground into coarse powder, add 6-10 times of water gaging, soak 1-5 hour, decocts 1-3 time, each 1-3 hour, filters, merging filtrate, and while being evaporated to 60 ℃ of hot surveys, relative density is 1.20-1.25
clearlycream, adds that ethanol is standing, precipitate with ethanol, filtration, and decompression filtrate recycling ethanol is to without alcohol taste, the fluid extract of relative density 1.00-1.10 when being evaporated to 60 ℃ of heat and surveying;
(3) fluid extract of step (2) gained is prepared into pharmaceutically acceptable preparation.
8. according to a kind of described in claim 1-5 any one Cordyceps fungus powder compound preparation that ferments, in preparation, improve the application in the medicine of sub-health status, treatment hypoimmunity or respiratory system disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310392296.1A CN103432173B (en) | 2013-08-27 | 2013-08-27 | Fermented fermentative cordycep fungal powder compound preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310392296.1A CN103432173B (en) | 2013-08-27 | 2013-08-27 | Fermented fermentative cordycep fungal powder compound preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103432173A CN103432173A (en) | 2013-12-11 |
| CN103432173B true CN103432173B (en) | 2014-10-22 |
Family
ID=49685959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310392296.1A Active CN103432173B (en) | 2013-08-27 | 2013-08-27 | Fermented fermentative cordycep fungal powder compound preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103432173B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105168967A (en) * | 2015-10-28 | 2015-12-23 | 青海尤尼克生物技术有限公司 | Health-care Chinese wolfberry fruit composition and preparation method thereof |
| CN107174630A (en) * | 2017-05-08 | 2017-09-19 | 张友明 | A kind of carbuncle gram ball |
| CN108065369A (en) * | 2017-12-27 | 2018-05-25 | 青海珠峰冬虫夏草保健品有限公司 | A kind of Hirsutella hepiali Chen et Shen powder health products |
| CN111012867A (en) * | 2019-12-23 | 2020-04-17 | 刘海波 | Cordyceps sinensis mycelium tablet and preparation method thereof |
| CN111358888B (en) * | 2020-05-11 | 2022-04-29 | 青海珠峰冬虫夏草工程技术研究有限公司 | Traditional Chinese medicine composition for treating pulmonary fibrosis and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101301413A (en) * | 2007-07-31 | 2008-11-12 | 四川回春堂生物科技有限公司 | Cordyceps sinensis and Rhodiola rosea capsules and preparation thereof |
| CN102406163A (en) * | 2010-09-17 | 2012-04-11 | 江中药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of health food or medicament for preventing and relieving physical fatigue |
| CN102688337A (en) * | 2012-06-05 | 2012-09-26 | 张俊 | Medicinal liquor for regulating qi and blood |
-
2013
- 2013-08-27 CN CN201310392296.1A patent/CN103432173B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101301413A (en) * | 2007-07-31 | 2008-11-12 | 四川回春堂生物科技有限公司 | Cordyceps sinensis and Rhodiola rosea capsules and preparation thereof |
| CN102406163A (en) * | 2010-09-17 | 2012-04-11 | 江中药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of health food or medicament for preventing and relieving physical fatigue |
| CN102688337A (en) * | 2012-06-05 | 2012-09-26 | 张俊 | Medicinal liquor for regulating qi and blood |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103432173A (en) | 2013-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432173B (en) | Fermented fermentative cordycep fungal powder compound preparation | |
| CN102028812B (en) | Chinese medicinal preparation for treating allergic rhinitis, allergic asthma and urticaria and preparation method thereof | |
| CN102327455B (en) | Traditional Chinese medicine for treating pediatric bronchitis, bronchial pneumonia and asthma | |
| EP1789062A1 (en) | Herb composition for asthma maintenance therapy and manufacturing method thereof | |
| CN101474377B (en) | Chinese medicine prescription for treating chronic bronchitis | |
| CN100389802C (en) | Medicine for treating and preventing chronic obstractive pneumonia | |
| CN103446414B (en) | Xiangmahanchuantie (XMHCT) and preparation technology | |
| CN102178892A (en) | Chinese medicinal composition for treating depression | |
| CN108065369A (en) | A kind of Hirsutella hepiali Chen et Shen powder health products | |
| CN103142923B (en) | Compound mongolian medicine preparation for treating coronary heart disease | |
| CN105412826A (en) | Pharmaceutical composition for treating bronchialasthma and application thereof | |
| CN109453325A (en) | A kind of Chinese medicine composition and its preparation method and application for treating respiratory disease | |
| CN103251813A (en) | Medicine for treating chronic bronchitis type tussive and preparation method thereof | |
| CN103690809B (en) | Traditional Chinese medicinal composition ointment for treating tuberculous pleuritis and preparation method thereof | |
| CN102228609B (en) | External foot plaster for treating cough and asthma of children | |
| CN106474216A (en) | A kind of Chinese medicine composition containing pennywort and preparation method thereof | |
| CN1112204C (en) | Traditional Chinese powder medicine for treating cough and preparation process thereof | |
| CN105250645A (en) | Traditional Chinese medicine for treating chronic bronchitis | |
| CN1286493C (en) | Medicine for treating asthma disease and its preparing method | |
| Xu et al. | Clinical observation on acupuncture plus acupoint sticking for bronchial asthma in remissive state | |
| WO2022257693A1 (en) | Traditional chinese medicine composition for treating hypertension and preparation method therefor | |
| CN103638296A (en) | Application of traditional Chinese medicine for treating coronary heart disease | |
| CN103877506A (en) | Medicament for treating epilepsy | |
| CN102688404A (en) | Thunberg fritillary bulb traditional Chinese medicine decoction for treating cough and preparation method thereof | |
| CN102688333A (en) | Traditional Chinese medicine decoction of snakegourd seed for treating cough and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 810001 Xining biological science and Technology Industrial Park, No. two, No. 16, Qinghai Patentee after: Wang Hui Address before: 810001 No. 19, Dongxin Road, Xining economic and Technological Development Zone, Qinghai, China Patentee before: Wang Hui |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180629 Address after: 810000 Qinghai biological science and Technology Industrial Park, Xining, Qinghai, No. 16, No. two road. Patentee after: Qinghai Mount Everest Cordyceps Medicine Co., Ltd. Address before: 810001 Qinghai Xining biological science and Technology Industrial Park, No. two Road 16. Patentee before: Wang Hui |